Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Lenalidomide

EU orphan designation number: EU/3/15/1473   
Active ingredient: Lenalidomide
Indication: Treatment of marginal zone lymphoma
Sponsor: Celgene Europe B.V.
Winthontlaan 6 N, 3526 KV Utrecht, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
28/04/2015 Orphan designation EMA/OD/284/14 (2015)2937 of 24/04/2015
27/07/2018 Transfer of orphan designation EMA/OD/284/14/T/01 (2018)5042 of 25/07/2018